Literature DB >> 33144436

Does the Addition of Abiraterone to Castration Affect the Reduction in Bone Mineral Density?

Shiori Nakajima1, Takamitsu Inoue2, Mingguo Huang1, Koichiro Takayama3, Soki Kashima1, Ryohei Yamamoto1, Atsushi Koizumi1, Taketoshi Nara1, Kazuyuki Numakura1, Mitsuru Saito1, Shintaro Narita1, Masatomo Miura4, Shigeru Satoh5, Tomonori Habuchi1.   

Abstract

BACKGROUND/AIM: The in vivo effect of abiraterone on bone mineral density (BMD) in addition to androgen deprivation therapy was examined using a murine model.
MATERIALS AND METHODS: The mice were separated into the following groups: control, abiraterone, castration, and castration+abiraterone. The percentage change in the ratio of bone to tissue volume (BV/TV), number of osteoblasts and osteoclasts, and the serum level of bone markers were compared on day 21.
RESULTS: The BV/TV ratio of the abiraterone, castration, and castration+abiraterone groups was lower than that of the control group. However, the change in the BV/TV ratio in the castration+abiraterone group was not significantly different from that in the castration group. There was no significant difference in the serum TRAP5b level and the number of osteoclasts and osteoblasts between the castration+abiraterone and the castration groups.
CONCLUSION: The addition of abiraterone to castration did not affect BMD in the murine model. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Androgen deprivation therapy; bone microenvironment; bone mineral density; micro-computed tomography; osteoblasts

Mesh:

Substances:

Year:  2020        PMID: 33144436      PMCID: PMC7811634          DOI: 10.21873/invivo.12167

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  25 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Matthew Smith; Chris Parker; Fred Saad; Kurt Miller; Bertrand Tombal; Quan Sing Ng; Martin Boegemann; Vsevolod Matveev; Josep Maria Piulats; Luis Eduardo Zucca; Oleg Karyakin; Go Kimura; Nobuaki Matsubara; William Carlos Nahas; Franco Nolè; Eli Rosenbaum; Axel Heidenreich; Yoshiyuki Kakehi; Amily Zhang; Heiko Krissel; Michael Teufel; Junwu Shen; Volker Wagner; Celestia Higano
Journal:  Lancet Oncol       Date:  2019-02-06       Impact factor: 41.316

3.  Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.

Authors:  Koichiro Takayama; Takamitsu Inoue; Shintaro Narita; Shinya Maita; Mingguo Huang; Kazuyuki Numakura; Hiroshi Tsuruta; Mitsuru Saito; Atsushi Maeno; Shigeru Satoh; Norihiko Tsuchiya; Tomonori Habuchi
Journal:  Cancer Lett       Date:  2017-03-31       Impact factor: 8.679

4.  Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.

Authors:  E Carton; G Noe; O Huillard; L Golmard; J Giroux; A Cessot; N E B Saidu; M Peyromaure; M Zerbib; C Narjoz; J Guibourdenche; A Thomas; M Vidal; F Goldwasser; B Blanchet; J Alexandre
Journal:  Eur J Cancer       Date:  2016-12-24       Impact factor: 9.162

5.  Nanomilled oral testosterone plus dutasteride effectively normalizes serum testosterone in normal men with induced hypogonadism.

Authors:  Stephanie T Page; William J Bremner; Richard V Clark; Mark A Bush; Hui Zhi; Ralph B Caricofe; Peter M Smith; John K Amory
Journal:  J Androl       Date:  2007-12-12

Review 6.  The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction.

Authors:  Abdulmaged M Traish; Andre Guay; Robert Feeley; Farid Saad
Journal:  J Androl       Date:  2008-07-17

7.  Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1995-07-29       Impact factor: 79.321

8.  Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

Authors:  M R Sydes; M R Spears; M D Mason; N W Clarke; D P Dearnaley; J S de Bono; G Attard; S Chowdhury; W Cross; S Gillessen; Z I Malik; R Jones; C C Parker; A W S Ritchie; J M Russell; R Millman; D Matheson; C Amos; C Gilson; A Birtle; S Brock; L Capaldi; P Chakraborti; A Choudhury; L Evans; D Ford; J Gale; S Gibbs; D C Gilbert; R Hughes; D McLaren; J F Lester; A Nikapota; J O'Sullivan; O Parikh; C Peedell; A Protheroe; S M Rudman; R Shaffer; D Sheehan; M Simms; N Srihari; R Strebel; S Sundar; S Tolan; D Tsang; M Varughese; J Wagstaff; M K B Parmar; N D James
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 32.976

Review 9.  Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.

Authors:  Cindy Strehl; Johannes W J Bijlsma; Maarten de Wit; Maarten Boers; Nele Caeyers; Maurizio Cutolo; Bhaskar Dasgupta; William G Dixon; Rinie Geenen; Tom W J Huizinga; Alison Kent; Annette Ladefoged de Thurah; Joachim Listing; Xavier Mariette; David W Ray; Hans U Scherer; Raphaèle Seror; Cornelia M Spies; Simon Tarp; Dieter Wiek; Kevin L Winthrop; Frank Buttgereit
Journal:  Ann Rheum Dis       Date:  2016-03-01       Impact factor: 19.103

10.  Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.

Authors:  Penelope D Ottewell; Ning Wang; Joshua Meek; C Anne Fowles; Peter I Croucher; Colby L Eaton; Ingunn Holen
Journal:  Endocr Relat Cancer       Date:  2014-07-22       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.